jeudi 5 juillet 2018

Onco Actu du 5 juillet 2018

Pour info : Onco Actu interrompt sa parution pendant deux semaines. 
Rendez-vous le 23 juillet !

4.2 Dép., diag. & prono. - Génome

As the NHS celebrates 70 years Genomics England sequences its 70,000th genome [Genomics England]

4.7 Dép., diag. & prono. - Col de l'utérus

HPV testing could be more accurate than smear tests for initial screening of cervical cancer [NHS Choices]

5. Traitements

Pancreatic Cancer Study Suggests Potential of Molecularly Tailored Treatments [Genome Web]

5.10 Traitements - Essais

Getting results: why NHS clinical trials are the envy of the world [The Guardian]

UK's top surgeon calls for new procedures to undergo clinical trials [The Guardian]

5.12.5 Immunothérapies - Pharma

Compugen Announces FDA Clearance of IND Application for COM701, a First-in-Class Immuno-Oncology Therapeutic Antibody [Compugen]

Compugen Advancing Cancer Immunotherapies to Clinical Trials [GEN News]

5.12.8 Immunothérapies - Economie

Final NICE no for BMS’ Opdivo in urothelial carcinoma [PharmaTimes]

5.2 Pharma

Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine [Exelixis]

Data show Imnovid-based triple therapy PFS benefit in blood cancer [PharmaTimes]

5.3.4 Traitements - AMM (FDA, EMA,...)

EMA Recommends Extension of Indications for Lenvatinib [ESMO]

5.4 Traitements - Economie

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [NICE]